QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.
Los Angeles, CA -- (SBWIRE) -- 01/08/2019 -- This report studies the global Alpha 1 Antitrypsin Deficiency Treatment market status and forecast, categorizes the global Alpha 1 Antitrypsin Deficiency Treatment market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called "additional therapies"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).
Request Sample Report Copy@ https://www.qyresearch.com/sample-form/form/547646/global-alpha-1-antitrypsin-deficiency-treatment-market
The global Alpha 1 Antitrypsin Deficiency Treatment market is valued at 1190 million US$ in 2017 and will reach 2560 million US$ by the end of 2025, growing at a CAGR of 10.1% during 2018-2025.
The major manufacturers covered in this report
Teva Pharmaceutical Industries
Applied Genetic Technologies
Arrowhead Research Corporation
ProMetic Life Sciences
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
Get Amazing Discount on Market Research Report@ https://www.qyresearch.com/request-discount/form/547646/global-alpha-1-antitrypsin-deficiency-treatment-market
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.